相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns
O. Humbert et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Evaluating response to immunotherapy with 18F-FDG PET/CT: where do we stand?
Nicolas Aide et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors
Takehiro Tozuka et al.
BMC CANCER (2020)
Pitfalls of a Mixed Metabolic Response at PET/CT
Michael S. Clark et al.
RADIOGRAPHICS (2019)
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
M. Tazdait et al.
EUROPEAN JOURNAL OF CANCER (2018)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer
Zhong-Yi Dong et al.
ONCOLOGIST (2017)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer
Erik J. van Helden et al.
PLOS ONE (2016)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer
Alain Hendlisz et al.
PLOS ONE (2015)
Clinical Significance of Heterogeneity in Response to Retreatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Lung Cancer Acquiring Secondary Resistance to the Drug
Youngjoo Lee et al.
CLINICAL LUNG CANCER (2014)
18F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma
Matteo S. Carlino et al.
EUROPEAN JOURNAL OF CANCER (2013)
The causes and consequences of genetic heterogeneity in cancer evolution
Rebecca A. Burrell et al.
NATURE (2013)
Influence of tumour micro-environment heterogeneity on therapeutic response
Melissa R. Junttila et al.
NATURE (2013)
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy
A. Hendlisz et al.
ANNALS OF ONCOLOGY (2012)
Intratumor Heterogeneity: Evolution through Space and Time
Charles Swanton
CANCER RESEARCH (2012)
Heterogeneity of Metabolic Response to Systemic Therapy in Metastatic Breast Cancer Patients
V. Huyge et al.
CLINICAL ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Richard L. Wahl et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography
Caroline Rousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical features of metastatic bone disease and risk of skeletal morbidity
Robert E. Coleman
CLINICAL CANCER RESEARCH (2006)
Bone imaging in metastatic breast cancer
T Hamaoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
分享论文
